CHAPEL HILL, NORTH CAROLINA--(Marketwire - January 04, 2011) - Adherex Technologies Inc. (TSX: AHX)(PINK SHEETS: ADHXF)(the "Company"), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, today announced that Rosty Raykov, Chief Executive Officer, will present at the Sidoti & Company, LLC Semi-Annual New York Micro-Cap Conference at 10:00 am on Monday, January 10, 2011 in the Estate 4/Carnegie Hall room at the Grand Hyatt New York Hotel, Park Avenue at Grand Central Station.
The event is available to on-site attendees only. Conference participants may arrange one-on-one meetings with Mr. Raykov in advance by contacting Justin Ruiss at firstname.lastname@example.org or calling 212-453-7008. A copy of the investor presentation will be available at the Adherex corporate website: www.adherex.com/investors-media/presentations.
In April 2010, Adherex completed a non-brokered CDN$7.2 million financing. The company intends to use these proceeds to advance the clinical development of eniluracil and for other general corporate purposes. "Given our strengthened financial profile and approximately 70% insider ownership, attending the Sidoti & Co. conference is our first step to establish relationships with new investment professionals, investment advisors, and money managers focused on the microcap market space. I believe this will allow Adherex to build and maintain an informed investor audience in both the U.S. and Canadian marketplace." said Mr. Rosty Raykov, Chief Executive Officer of Adherex.
Except for historical information described in this press release, all other statements are forward-looking. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2009. Adherex Technologies, Inc. disclaims any obligation to update these forward-looking statements except as required by law.
For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com